Canrenoate
Canrenoate (Potassium Canrenoate) is a potassium-sparing diuretic and aldosterone antagonist used to help manage fluid retention associated with conditions such as heart failure and certain cases of ascites. It works by blocking the effects of aldosterone, a hormone that promotes sodium and water retention, thereby increasing fluid excretion while reducing potassium loss. Depending on the formulation and clinical situation, it may be administered orally or by intravenous injection under medical supervision. Possible side effects include nausea, dizziness, low blood pressure, and electrolyte disturbances. Regular monitoring of kidney function and blood potassium levels is important because the medicine can cause hyperkalaemia, particularly in patients with impaired kidney function or those taking other potassium-raising medicines. Treatment should be prescribed and monitored by a qualified healthcare professional.
Canrenoate was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Canrenoate, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Canrenoate from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Canrenoate, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
